Ketoconazole (KTZ) is an imidazole derivative used in the oral treatment of mycotic infections (1) ; furthermore, it has a well-known blocking effect on steroid biosynthesis by inhibiting the cytochrome P-450 enzyme system. This has led to its use in clinical endocrinology in cases of hyperandrogenism and hypercortisolism, with favorable reports in the treatment of precocious puberty, hirsutism, breast or prostate cancer and Cushing's syndrome (2) (3) (4) (5) (6) (7) (8) .
KTZ exerts its antifungal action by inhibiting the conversion of lanosterol into ergosterol, since it also interferes with the 14a-demethylase of the microsomal cytochrome P-450 (9) and other enzyme systems as well. It results in an increase of membrane permeability, in the uptake inhibition of RNA and DNA precursors and in the inhibition of oxidative and peroxidative enzymes synthesis (10) .
In a short paper (11) , Namer et (12) .
Since these systems actively participate in thyroid cell fonction (13, 14) , together with the fact that other imidazole-derivatives affect thyroid metabolism (15) (Fig. 3a) . When this experiment was performed in the presence of bTSH, the inhibition was exerted even if KTZ was added immediately before the Na125I addition (Fig. 3b) .
The binding of bTSH to its solubilized receptor was not affected by KTZ 
